Unicycive Therapeutics, Inc. Common Stock UNCY

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

UNCY hizo una agrupación de acciones (split inverso) de 1:10 el 20 de junio de 2025: cada 10 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 5 oct

  ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

  A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. (UNCY) for allegedly making materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited its compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.

  

• GlobeNewswire Inc. 5 oct

  Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

  Unicycive Therapeutics faces a securities fraud class action lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The stock fell 39.1% on the news. The lawsuit alleges the company failed to disclose that it had not inspected its manufacturing vendor's facility or audited compliance with manufacturing practices, and lacked reasonable basis to believe deficiencies were resolved. The deadline to file a lead plaintiff motion is November 2, 2026.

  

• GlobeNewswire Inc. 5 oct

  Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for positive statements about regulatory approval prospects for oxylanthanum carbonate. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be eligible to join the case.

  

• GlobeNewswire Inc. 1 oct

  DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Hyliion Holdings Corp., Hims & Hers Health Inc., Unicycive Therapeutics Inc., and Baidu Inc. The lawsuits allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their respective businesses. Investors have until specified deadlines in late October and November 2026 to file lead plaintiff motions.

  

• GlobeNewswire Inc. 29 sept

  Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

  Unicycive Therapeutics faces a class action securities fraud lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The company's stock fell 39.1% following the announcement. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards.